Chalkis Longevity Science (ASX: 00767) has announced that on July 7, 2026, following trading hours, its wholly-owned subsidiary, Chalkis Health Industry Co.,Ltd., entered into a memorandum of cooperation with Shenzhen Zhongtou Huijin Fund Management Co., Ltd. (Shenzhen Zhongtou).

The planned collaboration involves the joint establishment of a dedicated health industry merger and acquisition fund, structured as a limited partnership, with a proposed total size of RMB 10 billion. The fund is intended to be raised in phases, with approximately RMB 2 billion in the first phase, RMB 3 billion in the second, and RMB 5 billion in the third.

This specialized M&A fund will focus its investments in entities operating within the longevity science, cell industry, longevity and anti-aging biopharmaceuticals, and high-end health management sectors. Shenzhen Zhongtou will be responsible for overseeing the fund's capital raising, investment activities, and management.

Shenzhen Zhongtou is a limited liability company established in China in 2001. It is a registered private fund manager with the Asset Management Association of China and primarily conducts private fund business under existing Chinese regulations, specializing in public market securities investment and primary/secondary equity investments.

Shenzhen Zhongtou has established and participates in the operation of similar industry funds across multiple provinces in China, including government development funds, industrial guidance funds, and listed company M&A funds. The firm currently manages or participates in managing funds with a total size of approximately RMB 100 billion, with intended signed fund scale reaching around RMB 1.2 trillion.

Chalkis Longevity Science is an investment holding company incorporated in Bermuda. Its subsidiaries are primarily engaged in longevity science businesses, lending and financial investment consulting, as well as securities, property, and investment operations.

Chalkis Health Industry Co.,Ltd. is a company established in China, mainly involved in providing health and longevity management services and the development and sales of related products, with a deep focus on the longevity science and cellular medicine industries.

The board of directors believes the prospects for the health and longevity science market are extensive. The proposed dedicated health industry M&A fund aims to become a leading fund in the longevity science sector, supporting the development of companies across the industry's supply chain.

Guided by principles of industry-finance integration, technological enablement, compliance, stability, and long-term value, the fund will concentrate on core areas such as cellular medicine, biopharmaceuticals, medical services, smart healthcare, and wellness. The goal is to jointly identify high-growth, high-barrier, and socially valuable projects to promote high-quality development within the longevity science industry.

Entering into this memorandum and pursuing the cooperation aligns with the group's longevity science business development strategy and plans, which is expected to benefit the group's future business growth.

The board believes the potential collaboration will further enhance the group's strategic positioning within the longevity science industry, opening up new revenue streams in this field and contributing to more stable and sustainable income growth for the group over the long term.